Anaptysbio, INC 8-K filings

AnaptysBio, Inc. announced the outcomes of its 2026 Annual Meeting of Stockholders, including the election of directors, ratification of its auditor, and approval of an amendment to its equity incentive plan.

AnaptysBio and defendants GlaxoSmithKline have agreed to a post-trial briefing schedule in their Delaware litigation concerning a collaboration agreement.

AnaptysBio has filed IRS Form 8937 to provide tax guidance regarding the recent spin-off of First Tracks Biotherapeutics.

AnaptysBio, Inc. announced a change in its fiscal year-end from December 31 to June 30, effective July 1, 2026.

AnaptysBio reported Q1 2026 financial results, highlighting strong Jemperli royalty growth and providing a business update following the spin-off of First Tracks Biotherapeutics.

AnaptysBio announces the appointment of Christopher M. Murphy as Chief Financial Officer and Owen Hughes as a Class I director, effective May 11, 2026.

AnaptysBio, Inc. has finalized the spin-off of its biopharma operations into the independent entity First Tracks Biotherapeutics, Inc.

AnaptysBio has finalized the spin-off of its biopharma operations into First Tracks Biotherapeutics, transitioning to a royalty management business model.

AnaptysBio's board approved the spin-off of First Tracks Biotherapeutics, which secured $80 million in private placement proceeds and will launch with $180 million cash, while AnaptysBio authorized a new $100 million stock repurchase plan.

AnaptysBio announces plans to separate into two publicly traded companies, revealing a robust cash position and significant clinical advancements for its immunology pipeline and royalty assets.

AnaptysBio has filed a lawsuit against TESARO and its parent GlaxoSmithKline, alleging material breaches of their collaboration agreement for the cancer drug dostarlimab (Jemperli) and seeking reversion of all rights.

AnaptysBio's Board of Directors authorized an additional $100 million for its stock repurchase plan, bringing the total available to $106.4 million.

AnaptysBio initiates legal action against Tesaro and GSK, alleging material breaches of their Collaboration and Exclusive License Agreement and tortious interference.

AnaptysBio announced the discontinuation of its ulcerative colitis trial for rosnilimab due to lack of efficacy, while highlighting positive Phase 2b rheumatoid arthritis data and plans to separate into two publicly traded companies by year-end 2026.

AnaptysBio reported strong Q3 2025 financial results driven by Jemperli sales and announced its intent to separate biopharma operations from royalty assets by year-end 2026.

AnaptysBio, Inc. presented positive clinical data for its lead programs ANB033 and rosnilimab, alongside plans to separate into two independent publicly traded companies.

AnaptysBio, Inc. announced plans to separate its business into two independent, publicly traded companies by the end of 2026, aiming to unlock and maximize shareholder value.

AnaptysBio announced positive Phase 2b data for rosnilimab in rheumatoid arthritis, strong financial results, and progress across its clinical pipeline, including a potential $75 million GSK milestone.

AnaptysBio, Inc. announced that its stockholders approved all five proposals at the 2025 Annual Meeting, including the election of three Class II directors and the amendment and restatement of its 2017 Equity Incentive Plan.

AnaptysBio announced positive six-month data from its Phase 2b RENOIR clinical trial for rosnilimab in rheumatoid arthritis, showcasing a best-in-disease profile with JAK-like efficacy and a favorable safety profile.

AnaptysBio reports positive Phase 2b results for rosnilimab in rheumatoid arthritis and provides a Q1 2025 financial update, including a $75 million stock repurchase program.

AnaptysBio's Board of Directors has authorized a stock repurchase plan of up to $75 million, supported by a strong cash position and anticipated milestone payment.

AnaptysBio reports positive Phase 2b results for rosnilimab in rheumatoid arthritis and provides a business update alongside its year-end 2024 financial results, highlighting a strong cash position.

AnaptysBio's corporate presentation highlights positive Phase 2b results for Rosnilimab in rheumatoid arthritis, progress in ulcerative colitis trials, and plans to out-license Etokimab, while projecting a strong cash runway through 2027.

AnaptysBio announces positive top-line data from its Phase 2b RENOIR trial of rosnilimab in rheumatoid arthritis, demonstrating statistical significance on primary and key secondary endpoints.

AnaptysBio has granted Vanda Pharmaceuticals an exclusive global license for imsidolimab, a drug for Generalized Pustular Psoriasis, in a deal worth up to $50 million plus royalties.

AnaptysBio's ANB032 did not meet primary or secondary endpoints in a Phase 2b trial for atopic dermatitis, but the company expects to have $415 million in cash reserves by the end of 2024.

AnaptysBio reported its third quarter 2024 financial results and provided updates on its clinical programs, including upcoming Phase 2b data readouts for its atopic dermatitis and rheumatoid arthritis drug candidates.

AnaptysBio, Inc. has entered into an underwriting agreement to sell 2,750,498 shares of its common stock at $36.50 per share, aiming to raise approximately $100 million.

AnaptysBio reported its second quarter 2024 financial results, highlighted by progress in its clinical trials and a strengthened cash position.